The role of chemotherapy in the treatment of adult soft tissue sarcomas
O'Byrne, Kenneth J. & Steward, W. P. (1999) The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology, 56(1), pp. 13-23.
Adult soft tissue sarcomas are relatively rare tumours which are curable with radical surgery. Approximately 50% of patients will develop inoperable disease or metastases for which chemotherapy may be inappropriate. Only two cytotoxic agents - doxorubicin and ifosfamide - have activity in > 20% of patients. For both these agents there is evidence of a dose-response relationship. There is currently no good evidence that combination chemotherapy confers a clinical benefit compared with single agents. Outside a clinical trial, standard first-line therapy should be with single agent doxorubicin at a dose intensity ≥ 70 mg2 every 3 weeks. Approximately 25% of patients may be expected to respond to this regimen. There is the suggestion that responses may occur to ifosfamide in patients who progress on doxorubicin. The role of chemotherapy in the adjuvant setting remains uncertain. Several trials have suggested a modest relapse-free and overall survival benefit for the use of post-operative chemotherapy and a recent overview of 14 randomised trials confirms a small though significant benefit. These benefits have to be weighed against the toxicity of chemotherapy. The importance of treating all patients with soft tissue sarcomas in clinical trials is stressed. There is an urgent need to define new active agents to treat this disease.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Adult, Chemotherapy, Soft tissue sarcomas, alkylating agent, alpha interferon, carboplatin, cisplatin, colony stimulating factor 1, cyclophosphamide, dacarbazine, dactinomycin, doxorubicin, etoposide, fluorouracil, ifosfamide, methotrexate, muramyl tripeptide, paclitaxel, topotecan, vincristine, vindesine, bone marrow suppression, cancer adjuvant therapy, cancer survival, clinical trial, dose response, drug efficacy, drug toxicity, human, metastasis, priority journal, relapse, review, risk benefit analysis, soft tissue sarcoma, treatment outcome, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Randomized Controlled Trials, Sarcoma|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 1999 S. Karger AG|
|Deposited On:||10 Dec 2013 02:11|
|Last Modified:||10 Dec 2013 02:11|
Repository Staff Only: item control page